Literature DB >> 8065570

Three-dimensional surface display of brain perfusion with 123I-IMP in Parkinson's disease.

H Tachibana1, K Kawabata, Y Tomino, M Sugita, M Fukuchi.   

Abstract

We reconstructed three-dimensional (3D) surface images from single-photon emission computed tomography (SPECT) data using N-isopropyl-p[123I]-iodoamphetamine (123I-IMP) in 27 patients with Parkinson's disease and 11 normal control subjects. The 3D reconstruction was performed using distance-shaded methods at threshold levels with an interval of 5% from 45-80%. Any area of decreased perfusion at each threshold level was visualised as a defect area by the algorithm. In nondemented patients with Parkinson's disease, perfusion defects were frequently found in the parietal cortex at a threshold value of 65%. In demented patients, perfusion defects were frequently seen at thresholds of 45-65%, and were more marked in the temporal and parietal cortex bilaterally. This suggests that dementia in Parkinson's disease is related to a reduction of perfusion in the temporoparietal cortex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065570     DOI: 10.1007/bf00593259

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  22 in total

1.  Correlation between regional cerebral blood flow and oxidative metabolism. In vivo studies in man.

Authors:  M E Raichle; R L Grubb; M H Gado; J O Eichling; M M Ter-Pogossian
Journal:  Arch Neurol       Date:  1976-08

2.  Alzheimer disease: quantitative analysis of I-123-iodoamphetamine SPECT brain imaging.

Authors:  R S Hellman; R S Tikofsky; B D Collier; R G Hoffmann; D W Palmer; S L Glatt; P G Antuono; A T Isitman; R A Papke
Journal:  Radiology       Date:  1989-07       Impact factor: 11.105

3.  Clinical application of three-dimensional surface display in brain imaging with Tc-99m HMPAO.

Authors:  J Ishimura; M Fukuchi
Journal:  Clin Nucl Med       Date:  1991-05       Impact factor: 7.794

4.  [99mTc]-HM-PAO SPECT in Parkinson's disease.

Authors:  G Pizzolato; M Dam; N Borsato; B Saitta; C Da Col; N Perlotto; P Zanco; G Ferlin; L Battistin
Journal:  J Cereb Blood Flow Metab       Date:  1988-12       Impact factor: 6.200

5.  Nonoxidative glucose consumption during focal physiologic neural activity.

Authors:  P T Fox; M E Raichle; M A Mintun; C Dence
Journal:  Science       Date:  1988-07-22       Impact factor: 47.728

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.

Authors:  D E Kuhl; E J Metter; W H Riege
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

8.  SPECT findings in Parkinson's disease associated with dementia.

Authors:  H Sawada; F Udaka; M Kameyama; N Seriu; K Nishinaka; K Shindou; M Kodama; N Nishitani; K Okumiya
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  Xenon contrast CT-CBF measurements in parkinsonism and normal aging.

Authors:  H Tachibana; J S Meyer; Y Kitagawa; N Tanahashi; P Kandula; R L Rogers
Journal:  J Am Geriatr Soc       Date:  1985-06       Impact factor: 5.562

10.  Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia.

Authors:  M Sasaki; Y Ichiya; S Hosokawa; M Otsuka; Y Kuwabara; T Fukumura; M Kato; I Goto; K Masuda
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.